A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability and blood levels of orally
administered anle138b as well as the effect of food and early signs of efficacy in patients
with mild to moderate Parkinson´s disease.
Phase:
Phase 1
Details
Lead Sponsor:
MODAG GmbH
Collaborators:
Aptuit (Verona) Srl, an Evotec Company Nottingham University Hospitals NHS Trust Quotient Sciences